Phaseline

Targets › CD3E

CD3E (T-cell surface glycoprotein CD3 epsilon chain): drug programs, companies and trials

48 programs from 39 companies in 447 trials: 236 Phase 2, 140 Phase 1, 66 Phase 3, 5 Phase 4; Oncology, Immunology, Metabolic and endocrine; next expected readout Nov 2026.

Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response. When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD247/CD3Z. All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain. (UniProt, P07766)

Open in Phaseline: the race on CD3E, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PfizerElranatamab
T cell surface glycoprotein CD3 binding agent; Tumor necrosis factor receptor superfamily member 17 binding agent
CD3E, CD3G, CD3D, TNFRSF17Phase 4Multiple Myeloma; Multiple Myeloma, Newly Diagnosed; Relapsed Refractory Multiple Myeloma (RRMM); Refractory Multiple Myeloma …May 2027
Regeneron PharmaceuticalsLinvoseltamab
anti-B-cell maturation antigen x anti-CD3 bispecific antibody
BCMA, GPRC5D, CD3E, TNFRSF17Phase 4Relapsed/Refractory Multiple Myeloma (RRMM); Relapsed and/or Refractory Multiple Myeloma (RRMM); Relapsed Refractory Multiple Myeloma (RRMM); High Risk Smoldering Multiple Myeloma (HR-SMM) …Aug 2027
Turun SongBCMA x CD3 Bispecific Antibody
BCMA x CD3 bispecific T-cell engager (BiTE) that engages B cells and plasma cells expressi
BCMA, CD3EPhase 4Antibody Mediated Rejection After Kidney TransplantationDec 2029
Wuhan YZY BiopharmaM701
anti-EpCAM and anti-CD3 human-mouse chimeric bispecific antibody
EPCAM, CD3EPhase 3Malignant Ascites; Malignant Pleural EffusionsDec 2026
RocheGlofitamab
B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent
MS4A1, CD3E, CD3G, CD3DPhase 3Lymphoma; Large B-Cell Lymphoma; Diffuse Large B-cell Lymphoma; Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma …Jan 2027
RocheMosunetuzumab
T cell surface glycoprotein CD3 binding agent; B-lymphocyte antigen CD20 binding agent
CD3E, CD3G, CD3D, MS4A1Phase 3Non-Hodgkin Lymphoma; Relapsed or Refractory Follicular Lymphoma; Lupus; B-cell Non-Hodgkin Lymphoma …Feb 2027
GenmabEpcoritamab
B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent
MS4A1, CD3E, CD3G, CD3DPhase 3Diffuse Large B-Cell Lymphoma; Diffuse Large B-cell Lymphoma; Follicular Lymphoma (FL); Non-Hodgkin Lymphoma …Mar 2027
Johnson & Johnson (Janssen)Talquetamab
T cell surface glycoprotein CD3 binding agent; G-protein coupled receptor family C group 5 member D binding agent
CD3E, CD3G, CD3D, GPRC5DPhase 3Multiple Myeloma; Hematological Malignancies; Relapsed/ Refractory Multiple Myeloma; Multiple Myeloma (MM) …Apr 2027
Johnson & Johnson (Janssen)Teclistamab
T cell surface glycoprotein CD3 binding agent; Tumor necrosis factor receptor superfamily member 17 binding agent
CD3E, CD3G, CD3D, TNFRSF17Phase 3Multiple Myeloma; Hematological Malignancies; Relapsed/ Refractory Multiple Myeloma; Multiple Myeloma (MM) …Apr 2027
Johnson & Johnson (Janssen)JNJ-79635322
Bispecific antibody targeting CD3 and BCMA
CD3E, TNFRSF17Phase 3Multiple Myeloma; Relapsed or Refractory Multiple MyelomaApr 2027
AmgenTarlatamab
T cell surface glycoprotein CD3 binding agent; Delta-like protein 3 binding agent
CD3E, CD3G, CD3D, DLL3Phase 3Small Cell Lung Cancer; Small Cell Lung Cancer (SCLC); Small-cell Lung Cancer; Extensive-Stage Small-Cell Lung Cancer …Apr 2027
AmgenBlinatumomab
T cell surface glycoprotein CD3 cross-linking agent; B-lymphocyte antigen CD19 cross-linking agent
CD3E, CD3G, CD3D, CD19Phase 3Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL); B Precursor Acute Lymphoblastic Leukemia; Systemic Lupus Erythematosus; B Cell Precursor Acute Lymphoblastic Leukemia …Oct 2027
Johnson & Johnson (Janssen)Ramantamig
BCMAxGPRC5DxCD3 trispecific antibody
TNFRSF17, CD3E, BCMA, GPRC5DPhase 3Multiple MyelomaDec 2027
AstraZenecasurovatamig (AZD0486)
Bispecific monoclonal antibody targeting CD20 and CD3E
CD19, CD3E, CD20Phase 3Large B-cell Lymphoma; Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV; Untreated Follicular Lymphoma; B-cell Non-Hodgkin Lymphoma …Jan 2028
AstellasASP2138
Bispecific antibody binding CLDN18.2 on tumor cells and CD3E on T cells
CD3E, CLDN18Phase 3Gastric Adenocarcinoma; Pancreatic Ductal AdenocarcinomaJan 2028
Regeneron PharmaceuticalsOdronextamab
B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent
MS4A1, CD3E, CD3G, CD3DPhase 3Follicular Lymphoma (FL); Diffuse Large B-cell Lymphoma (DLBCL); B-Cell Non-Hodgkin Lymphoma (B-NHL); Relapsed/Refractory Follicular Lymphoma …Feb 2028
Dana-Farber Cancer InstituteLinvoseltamab
Bispecific T cell engager targeting CD3 and BCMA
CD3E, BCMAPhase 3Multiple MyelomaOct 2033
Institute of Hematology & Blood Diseases Hospital, ChinaCM336
BCMA/CD3 bispecific antibody
BCMA, CD3EPhase 2Solitary Bone Plasmacytoma; Systemic Light Chain Amyloidosis; POEMS Syndrome; Immune Thrombocytopenia (ITP) …Dec 2026
University Hospital TuebingenCC-1
Bispecific antibody targeting PSMA and CD3
FOLH1, CD3EPhase 2Prostate Cancer; Castration-Resistant Prostatic Cancer; Prostate Cancer RecurrentDec 2026
Keymed Biosciences Co.LtdCM336
BCMA/CD3 bispecific antibody
BCMA, CD3E, TNFRSF17Phase 2Primary Light-Chain Amyloidosis; Multiple Myeloma; Autoimmune Cytopenia; Autoimmune Bullous DiseaseDec 2026
Mitchell Cairoalpha beta depletion (α/β CD3+/CD19+ cell depletion)
Selective depletion of alpha/beta T cells and CD19+ B cells from donor stem cells for allo
CD3E, CD19Phase 2Acute LeukemiaDec 2026
Tiziana Life SciencesForalumab (TZLS-401)
T cell surface glycoprotein CD3 inhibitor
CD3E, CD3G, CD3DPhase 2Non-Active Secondary Progressive Multiple Sclerosis; Secondary Progressive Multiple Sclerosis; Multiple System Atrophy; DementiaApr 2027
Institute of Hematology & Blood Diseases Hospital, ChinaGPRC5D/CD3 BiTEs
Bispecific T-cell engager targeting GPRC5D and CD3
GPRC5D, CD3EPhase 2Multiple Myeloma, Newly Diagnosed; Multiple Myeloma, Plasma Cell LeukemiaAug 2027
Memorial Sloan Kettering Cancer CenterElranatamab-bcmm
Bispecific antibody targeting BCMA and CD3
TNFRSF17, CD3EPhase 2Multiple MyelomaAug 2029
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Teplizumab
T-cell surface glycoprotein CD3 epsilon chain other
CD3EPhase 2Type 1 Diabetes MellitusNov 2029
Multiple Myeloma Research ConsortiumLinvoseltamab
B-cell maturation antigen (BCMA) × CD3 bispecific monoclonal antibody
TNFRSF17, CD3EPhase 2High Risk Newly Diagnosed Multiple MyelomaOct 2035
ImmunocoreIMC-R117C
PIWIL1 × CD3 bispecific ImmTAC protein
PIWIL1, CD3EPhase 1CancerNov 2026
Johnson & Johnson (Janssen)JNJ-78278343
KLK2-CD3 bispecific antibody (pasritamig)
KLK2, CD3EPhase 1Prostatic NeoplasmsDec 2026
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyA-319
CD19xCD3 bispecific antibody (T-cell redirecting)
CD19, CD3EPhase 1Systemic Lupus ErythematosusDec 2026
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)MK-4002 (HPN217)
Bispecific antibody targeting BCMA and CD3
BCMA, CD3EPhase 1Multiple Myeloma in RelapseDec 2026
Excyte BiopharmaYKST02
BCMA-CD3 bispecific antibody
BCMA, CD3EPhase 1Relapsed or Refractory Multiple MyelomaDec 2026
German Cancer Research CenterCC-3
Bispecific CD276xCD3 antibody
CD276, CD3EPhase 1Colorectal CancerMar 2027
Children's Oncology GroupFlotetuzumab
Interleukin-3 receptor subunit alpha binding agent; T cell surface glycoprotein CD3 binding agent
IL3RA, CD3E, CD3G, CD3DPhase 1Recurrent Acute Myeloid LeukemiaMar 2027
NextPoint TherapeuticsNPX372
B7-H7:CD3 bispecific antibody
PDCD7, CD3EPhase 1Metastatic Malignant NeoplasmApr 2027
Ruijin HospitalABO2203
mRNA encoding CD19/CD3 T cell engager
CD19, CD3EPhase 1B-cell Non-Hodgkin LymphomaMay 2027
Jeffrey Veale, MDCD34+ and CD3+ hematopoietic stem/progenitor cells
Donor-derived blood stem and T cells for facilitating mixed chimerism and immune tolerance
CD34, CD3EPhase 1Renal Transplant RejectionMay 2027
Mustafa Khasraw, MBChB, MD, FRCP, FRACPhEGFRvIII-CD3 (BRiTE)
Bispecific T cell engager with one arm binding CD3 on T cells and the opposing arm binding
EGFR, CD3EPhase 1Newly Diagnosed GlioblastomaDec 2027
SanofiSAR448501/DR-0201
Bispecific antibody targeting CD19 and CD3E
CD19, CD3EPhase 1B-cell Non Hodgkin Lymphoma; Systemic Lupus Erythematosus (SLE)Jan 2028
Shine-On BiomedicalSOA101
Nanobody-based trispecific antibody T cell engager targeting PD-L1/HLA-G/CD3
CD274, HLA-G, CD3EPhase 1Solid TumorsFeb 2028
Paul SzabolcsCD3/CD19 depleted leukocytes
Negative selection depleting CD3+ and CD19+ T cells and B cells from donor bone marrow via
CD3E, CD19Phase 1Sickle Cell AnemiaAug 2028
University of VirginiaCD33 FPBMC
anti-CD3 x anti-CD33 bispecific antibody armed fresh peripheral blood mononuclear cells
CD3E, CD33Phase 1Acute Myeloid LeukemiaAug 2028
BioAtlaBA3182
Conditionally active bispecific T-cell engager (BiTE) antibody targeting EpCAM and CD3
EPCAM, CD3EPhase 1Advanced AdenocarcinomaSep 2028
Shanghai Chia Tai Tianqing Pharmaceutical Technology DevelopmentTQB2934 injection
Bispecific antibody targeting BCMA and CD3
BCMA, CD3EPhase 1Systemic Light Chain AmyloidosisFeb 2029
AstraZenecaAZD5863
T cell-engaging bi-specific antibody targeting CLDN18.2 and CD3
CLDN18, CD3EPhase 1Gastric CancerMar 2029
Mabwell (Shanghai) Bioscience6MW5311
bispecific T cell engager antibody with bivalent binding to LILRB4 on tumor cells and mono
LILRB4, CD3EPhase 1AMLDec 2029
Cullinan TherapeuticsCLN-049
FLT3 x CD3 bispecific T cell engager
FLT3, CD3EPhase 1Relapsed/Refractory Acute Myeloid Leukemia (AML)Dec 2029
Guangzhou ExcelmabEX103
CD3 and CD20 bispecific monoclonal antibody
CD3E, CD20Phase 1CD20-positive Non-Hodgkin Lymphoma–
AbbVieTNB-383B
BCMA x CD3 T-cell engaging bispecific antibody
BCMA, CD3EPhase 1Multiple Myeloma–

Conditions

Multiple Myeloma (75) Follicular Lymphoma (13) Acute Lymphoblastic Leukemia (13) Diffuse Large B-Cell Lymphoma (8) Large B-cell Lymphoma (8) Lymphoma (7) Multiple Myeloma (MM) (6) Relapsed Refractory Multiple Myeloma (RRMM) (6) B Acute Lymphoblastic Leukemia (6) Recurrent Diffuse Large B-Cell Lymphoma (5) B-cell Non-Hodgkin Lymphoma (5) Multiple Myeloma, Newly Diagnosed (5)

Modalities

mixed (21), small molecule (15), antibody (7), protein or peptide (3), other (2)

Companies

Johnson & Johnson (Janssen) (5) Regeneron Pharmaceuticals (2) Amgen (2) Institute of Hematology & Blood Diseases Hospital, China (2) Roche (2) AstraZeneca (2) Tiziana Life Sciences (1) Sanofi (1) Ruijin Hospital (1) Shine-On Biomedical (1) Pfizer (1) Cullinan Therapeutics (1) Wuhan YZY Biopharma (1) Genmab (1) Paul Szabolcs (1) Jeffrey Veale, MD (1) Keymed Biosciences Co.Ltd (1) Astellas (1) German Cancer Research Center (1) Mabwell (Shanghai) Bioscience (1)

Related targets

CD3G (11) CD3D (11) BCMA (10) TNFRSF17 (8) CD19 (7) MS4A1 (4) GPRC5D (4) CD20 (2) EPCAM (2) CLDN18 (2) DLL3 (1) CD274 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.